{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034961","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.009434+00:00","generated_at":"2026-06-04T09:15:12.357526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ProKidney FY2023 net loss $135.4M; cash $363M; positive Phase 2 data; mfg pause","bullets":["Net loss before noncontrolling interest $135.4M vs $148.1M in 2022; cash $363.0M, funding into Q4 2025.","R&D expenses $106.7M, up $24.6M on Phase 3 costs; G&A $44.8M, down $26.1M on lower equity comp.","Appointed Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as Chief Business Officer.","Positive interim Phase 2 RMCL-002 data showed kidney function preservation; PROACT 1 enrollment modified to eGFR 20-35.","Manufacturing paused for protocol amendment and QP audit; expects PROACT 1 and PROACT 2 enrollment to resume mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034961","json":"https://secwatch.observer/filing/0000950170-24-034961.json","markdown":"https://secwatch.observer/filing/0000950170-24-034961.md","text":"https://secwatch.observer/filing/0000950170-24-034961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024034961/0000950170-24-034961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024034961/prok-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:15:12.357526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c04f632151e1e25eed8d48a3d3f5ad3c3e9041cc","claim":"PROKIDNEY CORP. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"ProKidney Corp. issued a press release to announce its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024034961/0000950170-24-034961-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}